Barbara Burtness, MD, Yale Cancer Center, New Haven, CT, talks on what she is most excited about at the IASLC 2022 World Conference on Lung Cancer congress, including data on cohorts of patients who have been treated with KRAS inhibitors including KRASG12C-mutant lung cancer. Dr Burtness is curious about data including on clinical predictors for response and molecular markers such as in co-mutations with STK11 and KEAP1 as well as on the impact on the immune system of KRASG12C inhibitors. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.